AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02616809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increasing energy expenditure
Description: Participants will cycle slowly while seated in prescribed hourly intervals. This condition will increase energy expenditure while keeping a sitting posture
Study NCT02616809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Changing posture
Description: Participants will transition from sitting to standing in prescribed hourly intervals. This condition will change posture (sit to stand) while maintaining low energy expenditure
Study NCT02616809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increasing energy expenditure and changing posture
Description: Participants will transition from sitting to a walking workstation in prescribed hourly intervals. This condition will both increase energy expenditure and change posture.
Study NCT02047071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airways pressure
Description: Optimal Continuous positive airways pressure treatment every night plus standard care for OSA consisting of hygienic-dietary advice and lifestyle counseling.
Study NCT01574001 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Antismoking intervention with no early follow-up
Description: an anti-smoking intervention in line with the 5A's method without early follow-up; follow-up assessment will be limited to two visits: 3 and 12 months after stroke
Study NCT01574001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antismoking intervention with minimal early follow-up
Description: Anti-smoking intervention in line with the 5A's method (Ask, Advice, Assess, Assist, Arrange follow-up. The intervention will be carried out 5-7 days after stroke, before the planned discharge from the hospital. Seven days after discharge from a stroke unit a brief telephone/personal advice will be given aimed to motivate patients to quit smoking; follow-up assessment will include two visits: 3 and 12 months after stroke
Study NCT01574001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antismoking intervention with intensive early follow-up
Description: an anti-smoking intervention in line with the 5A's method will be given, including four follow-up visits within 6 weeks after discharge from the hospital (week 1, week 2, week 4, week 6 after stroke); follow-up assessment will include two visits: 3 and 12 months after stroke
Study NCT00213304 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: varicella vaccine (VARIVAX)
Study NCT03694665 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lung recruitment maneuver
Description: A Lung recruitment maneuver is aimed to resolve atelectasis during mechanical ventilation. It consists in a brief and controlled increment in airways pressure using pressure control ventilation. Positive end-expiratory pressure (PEEP) is increases every 5 centimeters of water (cmH2O), from 0 to 20 cmH2O keeping a fixed driving pressure of 20 cmH2O. A final step of 40 cmH2O of plateau pressure was maintained for 10 breaths, returning then to standard ventilatory settings.
Study NCT03613337 — intervention group
Intervention type: OTHER
Intervention: clinical restenosis
Description: The primary endpoints is clinical restenosis, the investigators will compared the incidence of clinical restenosis by different smoking status.
Study NCT01765478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM71224 single ascending dose
Study NCT01352481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early parent-based speech intervention program
Description: Seven 1h sessions during a three-month period.
Study NCT01765478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM71224 food effect
Study NCT01765478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM71224 Multiple ascending dose
Study NCT00223236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citicoline
Description: Citicoline or placebo will be given beginning at one table (500mg)/day with an increase to two tablets (1000mg)/day at week 2, three tablets (1500mg)/day at week 4 and four tablets (2000mg)/day at week 6. Patients will remain on 2000mg/day through week 12. Doses will be decreased if needed due to side effects.
Study NCT00223236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching active medication in all other aspects.
Study NCT02122068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentalizing Imagery Therapy
Description: 4 week long meditation and mindfulness intervention
Study NCT02122068 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation cd
Study NCT00835731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol
Description: 400mcg misoprostol, buccal administration, 1 time dosing 3-4 hours before abortion by D\&E
Study NCT00835731 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dilapan-S, vitamin B-12
Description: One Dilapan-S rod placed in the cervix 3-4 hours before abortion by D\&E. Control: 1000mcg vitamin B-12, buccal administration 3-4 hours before abortion by D\&E
Study NCT02146339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cheese n°1- cheese n°2 - cheese n°3
Description: Each subject will receive a single dose of cheese n°1, then cheese n°2 after a wash-out period of 4 weeks, then cheese n°3 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product
Study NCT02146339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cheese n°1- cheese n°3 - cheese n°2
Description: Each subject will receive a single dose of cheese n°1, then cheese n°3 after a wash-out period of 4 weeks, then cheese n°2 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product
Study NCT02146339 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cheese n°2 - cheese n°1- cheese n°3
Description: Each subject will receive a single dose of cheese n°2, then cheese n°1 after a wash-out period of 4 weeks, then cheese n°3 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product
Study NCT02146339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cheese n°2- cheese n°3 - cheese n°1
Description: Each subject will receive a single dose of cheese n°2, then cheese n°3 after a wash-out period of 4 weeks, then cheese n°1 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product
Study NCT02146339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cheese n°3 - cheese n°1- cheese n°2
Description: Each subject will receive a single dose of cheese n°3, then cheese n°1 after a wash-out period of 4 weeks, then cheese n°2 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product
Study NCT02146339 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cheese n°3- cheese n°2 - cheese n°1
Description: Each subject will receive a single dose of cheese n°3, then cheese n°2 after a wash-out period of 4 weeks, then cheese n°1 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product
Study NCT03353740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68 labeled PSMA-11 PET
Description: Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
Study NCT02846220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overcoming Immunity to Change health coaching
Study NCT03195400 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oral Glucose Tolerance Test
Description: The oral glucose tolerance test (OGTT) measures the body's ability to use a type of sugar, called glucose, that is the body's main source of energy. An OGTT can be used to diagnose prediabetes and diabetes.
Study NCT02184637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Description: A dark pink, capsule-shaped, film-coated tablet containing 150mg tafenoquine. To be administered orally
Study NCT02184637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin + Piperaquine tetraphosphate
Description: White, oblong, biconvex, film-coated tablet with a break-line and marked on one side with two σ letters containing 320 mg piperaquine tetraphosphate (as the tetrahydrate; PQP) and 40 mg dihydroartemisinin (DHA). To be administered orally
Study NCT01077596 — intervention group
Intervention type: DRUG
Intervention: Regular bupropion use
Description: Regular use of bupropion is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
Study NCT02184637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether + Lumefantrine
Description: Light yellow, round tablet with NC debossed on one side and CG on the other, containing 20 mg artemether and 120 mg lumefantrine. To be administered orally
Study NCT01963494 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic planning intervention
Description: Dyadic planning refers to creating together with a partner if-then plans on when, where, and how the individual target person will implement a new behaviour.
Study NCT01963494 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual planning intervention
Description: Target persons form action plans on their own.
Study NCT01963494 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General motivational treatment
Description: Both partners are asked to read a brochure that aims at enhancing their motivation to increase levels of moderate physical activity. They respond to a quiz afterwards.
Study NCT01077596 — intervention group
Intervention type: DRUG
Intervention: Regular SSRI (Selective serotonin reuptake inhibitors) use
Description: Regular use of SSRI is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
Study NCT01077596 — intervention group
Intervention type: DRUG
Intervention: Regular TCA (Tricyclic antidepressants) use
Description: Regular use of TCA is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
Study NCT01077596 — intervention group
Intervention type: DRUG
Intervention: Regular use of any other antidepressant
Description: Regular use of any other antidepressants is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date. An other antidepressant would be any antidepressant other than bupropion, a SSRI or a TCA.
Study NCT01963494 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General motivational treatment
Description: Both partners are asked to read a brochure that aims at enhancing their motivation to increase levels of moderate physical activity. They respond to a quiz afterwards.
Study NCT04796519 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Description: Surgical procedure
Study NCT02965157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART20
Study NCT01551745 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vigil™ Vaccine
Description: Patients meeting eligibility criteria will receive Autologous Vigil™ vaccine will be supplied by Gradalis,Inc. Patients will receive 1.0 x 10e7 cells via intradermal injection one day each cycle for a maximum of 12 doses as long as sufficient material is available and subject is clinically stable. Additionally, patients will receive bevacizumab 10 mg/kg intravenously (prior to Vigil™ administration) every 2 weeks (4 weeks=1 cycle).
Study NCT01551745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients meeting eligibility criteria will receive bevacizumab 10 mg/kg intravenously every 2 weeks.
Study NCT01652924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation with facial mask
Description: This group includes patients with the randomization process are assigned to mechanical ventilation with facial mask during induction of anesthesia, which will be maintained until to secure airway with endotracheal tube to determine the presence of gastric insufflation. The size of the facial mask is used according to the age and ventilation parameters are: inspiratory pressure 10 cmH2O, PEEP 5 cmH2O, respiratory frequency and relation I/E according to age .
Study NCT01652924 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual ventilation with facial mask
Description: This group includes patients with the randomization process are allocated to manual ventilation with facial mask during induction of anesthesia, which will be maintained until to secure airway with endotracheal tube to determine the presence of gastric insufflation.~The size of the facial mask is used according to the age and ventilator y parameters are selected by the anesthesiologist.
Study NCT02413203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Blood and urine collections before and 3 hours after celecoxib administration.
Study NCT02413203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blood and urine collections before and 3 hours after placebo administration.
Study NCT01851837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise time
Description: Continuous training, Interval training
Study NCT01105390 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rilotumumab
Description: Given IV
Study NCT01105390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT01105390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV
Study NCT01105390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04420130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab was administered 200mg iv every 3 weeks
Study NCT03195400 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hyperglycemic Clamp
Description: Test of beta-cell function and insulin secretion. Involves increasing and maintaining blood glucose concentration with IV variable infusion of dextrose.
Study NCT03195400 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Isoglycemic Intravenous Glucose Test
Description: Test which exposes pancreas to blood glucose levels matched to the ones obtained at the OGTT.
Study NCT03195400 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hyperinsulinemic Euglycemic Clamp and 2H20
Description: Test is used to assess insulin effects on hepatic glucose production.
Study NCT04420130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: The chemotherapy regimen may be a standard regimen for routine treatment of advanced pancreatic cancer.
Study NCT03302364 — intervention group
Intervention type: DRUG
Intervention: Risperidone
Description: patients who have never received risperidone or who have received re-administration of risperidone after discontinuation of risperidone treatment
Study NCT04363190 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cytogenetic analysis
Description: 1. FISH study using the UroVysion kit in interphase peripheral lymphocytes, that allows the study of numerical aberrations for chromosomes 3, 7 and 17 and locus 9p21.~2. G banding study to analyse the whole karyotype study regarding both numerical and structural aberrations during metaphase.~3. Sister chromatid exchanges (SCE) analysis with bromodeoxyuridine (BrdU) staining for the whole karyotype during metaphase: analizing the proportion of SCE per metaphase (NSM).
Study NCT03351101 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Senofilcon C
Description: Senofilcon C Contact Lens
Study NCT03351101 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Samfilcon A
Description: Samfilcon A Contact Lens
Study NCT00222131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Esomeprazole 40 mg QD
Study NCT00222131 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03095196 — intervention group
Intervention type: DEVICE
Intervention: Multipolar CRT-d, plus conventional drug therapy for HF.
Description: A random CRT-d implant performed via multipolar left ventricle lead, in failing heart patients treated by maximal drug therapy.
Study NCT03095196 — intervention group
Intervention type: DEVICE
Intervention: Bipolar CRT-d, plus conventional drug therapy for HF.
Description: A random CRT-d implant performed via bipolar left ventricle lead (group B), in failing heart patients treated by maximal drug therapy.
Study NCT03095196 — intervention group
Intervention type: DRUG
Intervention: HF drugs
Description: full medical therapy to treat HF symptoms and its progression.
Study NCT04420130 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: First give pancreatic cancer patients with liver metastases to ablation of liver metastases
Study NCT03475212 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Virus Specific T-cell (VST) infusion
Description: Patients will receive partially HLA-matched VSTs as a single infusion. Patients who have a partial response (>1 log decrease in viral load without clearance) or no response and do not have treatment-related dose-limiting toxicities are eligible to receive up to 3 additional doses from day 30 after the initial infusion and at 2 weekly intervals thereafter. The viral load of the virus (or viruses) that patients are initially treated for are monitored by viral PCR.
Study NCT05685940 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venapuncture
Description: Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of risankizumab.
Study NCT05685940 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient questionnaires
Description: The study participants will complete the Dermatology Quality of Life (DLQI) and EQ-5D-5L questionnaire at each study visit.
Study NCT01784796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Description: 8 week Mindfulness Based Stress Reduction Program
Study NCT01784796 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Program
Description: 8 week Health Education Program
Study NCT02257801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional beverage fortified with 6mg lutein/day
Description: 2 beverages (each containing 3mg lutein) per day (total of 6mg lutein/day) for a total of 4 months
Study NCT02257801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional beverage fortified with 12mg lutein/day
Description: 2 beverages (each containing 6mg lutein) per day (total 12mg lutein/day) for a total of 4 months
Study NCT02257801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional beverage fortified with 12mg lutein/day
Description: 2 beverages (each containing 0mg lutein) per day (total 0mg lutein/day) for a total of 4 months
Study NCT03708393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imagio (IUS+OA)
Description: The Imagio ultrasound and opto-acoustic images to be reviewed as part of the reader study
Study NCT03708393 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Imagio Ultrasound
Description: Imagio ultrasound images to be reviewed as part of the reader study
Study NCT03708393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mammography
Description: Mammography images as available per standard of care
Study NCT03708393 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mammography
Description: Mammography images as available per standard of care
Study NCT00839176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-10100
Description: Extended-release tablet, 5\~15mg, twice day (morning \& evening) at least 30 min before meal, 8 weeks
Study NCT00839176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RX-10100
Description: Extended-release tablet, 5\~15mg, twice day (morning \& evening) at least 30 min before meal, 8 weeks
Study NCT03881761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/CD20 bispecific CAR-T cells
Description: collecting blood for CAR-T cells culture three days later, FC regimen (fludarabine 30mg/m2/d x 3, cyclophosphamide 600-800mg/m2/d x 2) another two days later, transfusing CD19/CD20 bispecific CAR-T cell with a dose of 1-3x106/kg
Study NCT03425474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosilate
Description: Initial dose plus supplemental doses as necessary
Study NCT03425474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Initial dose plus supplemental doses as necessary